Biomarker Changes Associated With Both Dulaglutide and Cardiovascular Events in the REWIND Randomized Controlled Trial: A Nested Case-Control Post Hoc Analysis
Authors' conclusion
Dulaglutide was associated with a reduced 2-year rise from baseline of NT-proBNP and GDF-15. Higher rises of these biomarkers were also associated with MACE.
Study context
- Population
- REWIND participants with stored fasting baseline and 2-year plasma samples; 19 protein biomarkers (824 major adverse cardiovascular events (MACE), 845 matched non-MACE) and 135 metabolites (600 MACE, 601 matched non-MACE)matched case-control
- Comparison
- Dulaglutide vs placebo; MACE cases vs matched non-MACE controls
- MACEn = 824
- Non-MACEn = 845reference
- Primary endpoint
- Biomarkers associated with both dulaglutide treatment and MACE (2-year changes in 19 proteins and 135 metabolites)
- Follow-up
- 2 years
Methodological detailsmatched
- Matched
Primary result
As reported in the abstract
Estimate (95% CI)P value
MACEvs Non-MACE
OR (NT-proBNP increase) 1.267(1.119–1.435)
P < 0.001MACEvs Non-MACE
OR (GDF-15 increase) 1.937(1.424–2.634)
P < 0.001Further findings
| Outcome | P value |
|---|---|
| Metabolites: dulaglutide vs placebo · 2 years | P < 0.001 |
- Metabolites: dulaglutide vs placebo: greater fall in 2-hydroxybutyric acid and greater rise in threonine with dulaglutide
Original publication
Biomarker Changes Associated With Both Dulaglutide and Cardiovascular Events in the REWIND Randomized Controlled Trial: A Nested Case-Control Post Hoc Analysis. Diabetes Care. Published 10 March 2023. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →